CERo Therapeutics Holdings, Inc. (CERO) stock
CEROOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as CEROW
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 4/30
$0.01+0.00 (0.00%)
Close on Oct 19, 2026Market cap $253.05KP/E –Yield 172833.33%
Earnings
CERo Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of CERo Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q3 FY2024ended Sep 30, 2024 | Oct 11, 2024after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
CERo Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When CERo Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases CERo Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Update
- Update
- News
- Update
- News
- News
- News
- News
- News
- Update
- News
- News
- News
- News
See a number that looks wrong?